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Abstract
Background: Portopulmonary hypertension (PPHTN) is a severe complication in liver cirrhosis.
PDE5 inhibitors lower pulmonary arterial pressure (PAP) in PPHTN. However, their effect on
portal hypertension has not yet been investigated.
Case presentation: A 55 year old male patient presented with PPHTN and alcoholic liver
cirrhosis. 10 mg of Tadalafil, a PDE5 inhibitor with a long half-life, was administered orally under
continuous monitoring of pulmonary and portal hemodynamics. For maintenance therapy the
patient received Sildenafil 20 mg bid.
Tadalafil lowered mean PAP from 45 to 39 mmHg within 60 minutes. Cardiac output (CO)
increased from 6.8 to 7.9 l/min. Central venous pressure (CVP) remained stable at 3 mmHg.
Systolic and diastolic blood pressure was lowered from 167/89 to 159/86 mmHg. Pulse rate
increased from 75 to 87 per min. Wedged hepatic vein pressure (WHVP) decreased from 21 to 18
mm Hg, hepatovenous pressure gradient (HVPG) decreased from 10 to 7 mmHg. Hemodynamic
monitoring after 6 months of Sildenafil therapy revealed a sustained lowering of mean PAP. HVPG
remained constant at 10 mmHg. Cardiac and pulmonary performance had further improved.
Conclusion: This case report shows for the first time, that phosphodiesterase 5 inhibitors lower
both portal and pulmonary pressure in portopulmonary hypertension.
Background
Liver cirrhosis may be complicated by the portopulmo-
nary hypertension (PPHTN), a combination of portal
hypertension and pulmonary hypertension. A dysregula-
tion of the NO-cGMP system as described for the liver
sinusoids in liver cirrhosis [1] may play an important role
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in PPHTN, too. Cytokines bypassing the liver via collat-
eral blood flow may lead to an imbalance of vasoactive
substances in pulmonary vessels, which respond with
active vasoconstriction and proliferation of endothelial
and smooth-muscle cells.
PPHTN has an estimated prevalence in liver transplant
candidates of 3–6%, and in patients with refractory ascites
as high as 16% and is the third most frequent type of pul-
monary arterial hypertension [2]. The prognosis is poor,
with a mean survival of 15 months after diagnosis and
even poorer in patients with a mean PAP > 35 mmHg.
After liver transplantation the risk of complications is
markedly elevated.
Beta-blockers – the standard medical treatment of portal
hypertension – worsen the prognosis of patients with
PPHTN [3]. Endothelin receptor blockers and prostacyc-
lin derivates used in idiopathic pulmonary hypertension
(IPAH) have also been tested in PPHTN with promising
results. PDE5 inhibitors, a recently accepted therapy of
IPAH [4], have been shown to lower PAP in PPHTN, too.
However, their effects on portal pressure have not been
investigated so far. We have shown that Vardenafil, an
PDE5 inhibitor with a short half-life, lowers portal pres-
sure in healthy subjects and patients with liver cirrhosis
[5]. Here we show that Tadalafil, a PDE5 inhibitor with a
long half-life, reduces both PAP and portal pressure in a
patient with PPHTN. Maintenance therapy with Sildenafil
improved the cardio-pulmonary performance without
negative effects on portal pressure.
Case presentation
A 55 year old male patient with Child A alcoholic liver cir-
rhosis was admitted to the hospital because of increasing
dyspnoea at exercise. He had been completely abstinent
from alcohol since 7 years. There was no prior history of
hemoptysis or gastrointestinal bleeding. The patient
reported two episodes of syncope initiated by exercise. He
was obese (186 cm, 108 kg). Examination of the heart and
the lungs was unremarkable. The liver was enlarged and
palpable. No edema was present. The patient could climb
3 flights of stairs (NYHA II). There were no signs of
hepatic encephalopathy. The patient received no current
medication.
Blood pressure was 140/105 mmHg, heart rate was 79/
min. ECG indicated a dilation of right atrium and
increased right heart pressure. Doppler echocardiogram
showed right heart enlargement with a PAPsystolic of about
75 mmHg and normal dimensions of the left ventricle
and atrium. Holter ECG did not reveal any severe arrhyth-
mias.
Abdominal duplex sonography showed a slow portal
blood flow (9 cm/s) and a reduced portal flow volume
(0.15 l/min) with intrahepatic retrograde perfusion. The
umbilical vein was open and a large splenorenal shunt
was detected. Ascites was absent. Second grade esophageal
varices were found at endoscopy.
Pathological laboratory findings were thrombocytopenia
(112.000/μl), prolonged prothrombin time (68%), ele-
vated bilirubin (3.3 mg/dl), and yGT (60 U/l). Spirometry
showed a normal vital capacity (5.35 l, 103% predicted)
and FEV1 (3.4 l, 86% predicted), respectively. Endexpira-
tory flow (MEF 25) was reduced to 0.5 l (22% predicted).
Six-minute walking distance was 522 m. Arterial blood
gas analysis before and after six-minute walking test
showed normal paO2 (74 and 75 mmHg) and paCO2 (35
and 32 mmHg). After exclusion of other causes of pulmo-
nary hypertension according to current guidelines portop-
ulmonary hypertension was diagnosed in this patient.
We tested the effect of 10 mg Tadalafil on pulmonary and
hepatic hemodynamics invasively in the short term after
right heart catheterization and introducing a balloon cath-
eter into an intermediate liver vein. As we already had
some experience with Sildenafil and Vardenafil, two other
PDE5 inhibitors, in liver cirrhosis, we were interested in
the effect of Tadalafil in this case. Tadalafil, the PDE5
inhibitor with a long half-life could be the most suitable
substance for long-term therapy. The hemodynamic test
was approved by the local ethics committee. Fig. 1 shows
the time course of pulmonary and hepatic hemodynamic
parameters. After 60 minutes PAPmean was reduced from
45 to 39 mmHg. Cardiac output increased from 6.8 to 7.9
l/min and pulmonary vascular resistance decreased from
Reduction of mean pulmonary arterial pressure (PAPmean;  solid square; mmHg) and hepatovenous pressure gradient  (HVPG; cross; mmHg), cardiac output (CO; black diamond; l/ minm2) and central venous pressure (CVP; gray triangle;  mmHg) after a single oral Tadalafil administration and after  Sildenafil therapy for the following 6 months Figure 1
Reduction of mean pulmonary arterial pressure (PAPmean; 
solid square; mmHg) and hepatovenous pressure gradient 
(HVPG; cross; mmHg), cardiac output (CO; black diamond; l/
minm2) and central venous pressure (CVP; gray triangle; 
mmHg) after a single oral Tadalafil administration and after 
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459 to 344 dyn·sec·cm-5. Arterial paO2 increased from
70.5 to 78.2 mmHg (Table 1). PAWP was 6 mm Hg, CVP
was 3 mm Hg before and 60 minutes after Tadalafil.
Wedged hepatic vein pressure (WHVP) decreased from 21
to 18 mmHg, free hepatic vein pressure (FHVP) remained
constant at 11 mmHg. HVPG (WHVP – FHVP) decreased
by 30%.
One week later the effect of Tadalafil on exercise capacity
was investigated (Table 1). Breath gas analysis with
cycling ergometry up to subjective exhaustion (120 W) at
baseline showed a VO2peak of 2020 ml/min. At maximum
exhaustion, VE/VCO2 was 35.2 and VE/VO2 was 37.0,
respectively. Cycling ergometry was repeated on the fol-
lowing day one hour after Tadalafil administration.
VO2peak  during cycling exercise was slightly increased
(2240 ml/min, 130 W) with a consistent decrease in VE/
VCO2  (33.2) and VE/VO2  (33.5) at 130 W. These
decreased ventilatory equivalent ratios (ventilation (VE)
divided by oxygen consumption (VO2) or carbon dioxide
release (VCO2)) reflect better ventilatory efficiency.
Thereafter, the patient received Sildenafil, since this PDE5
inhibitors is approved for treatment of IPAH. The dose
was reduced to 20 mg bid as compared to the dose used in
recent studies considering the altered pharmacology of
the drug in liver cirrhosis. Clinical symptoms and labora-
tory tests were recorded in our outpatient clinic. No
adverse side effects were seen. Six minutes walking test
after three months was unchanged, but was increased to
580 m after 6 months.
Six months after starting therapy with Sildenafil exercise
capacity and pulmonary hemodynamics were measured
again. Breath gas analysis during cycling exercise resulted
in an increased VO2peak (2640 ml/min, 140 W). A further
decrease in VE/VCO2 (27.8) and VE/VO2 (29.9) confirmed
an improved cardiopulmonary function.
8 hours after the morning Sildenafil dose hemodynamic
parameters were invasively measured before and 60 min-
utes after oral intake of 20 mg Sildenafil. After 60 minutes
PAPmean remained unchanged at 42 mmHg. Cardiac out-
put increased from 7.5 to 8.0 l/min, pulmonary vascular
resistance remained unchanged at 352 and 360
dyn·sec·cm-5, respectively. HVPG before Sildenafil was
10 mmHg (WHVP 21 mmHg, FHVP 11 mmHg). After 60
minutes the liver catheter was occluded by a small throm-
bus and WHVP and FHVP could not be determined.
Table 1: Hemodynamic and pulmonary parameters
After 3 months Sildenafil  After 6 months Sildenafil
Parameter Baseline After 60 minutes Tadalafil 60 min after the last dose 8 h after the last dose 60 min after 20 mg Sildenafil
Systolic BP (mmHg) 167 159 147 145 140
Diastolic BP (mmHg) 89 86 97 100 90
Heart rate (1/min) 75 87 93 69 75
Cardiac index (l/minm2) 3.02 3.51 3.33 3.56
Cardiac output (l/min) 6.8 7.9 7.5 8.0
Mean PAP (mmHg) 45 39 42 42
PVR (dyn·s-1·cm-5) 459 344 352 360
Central venous pressure 
(mmHg)
33 6 3




Arterial paO2 (mmHg) 70.5 78.2 71.4 76.9
Arterial paCO2 (mmHg) 41.3 38.4 35.3 31.3
6 min walking test (m) 522 514 580
VO2peak (ml/min) 2020 2240 2640
Watt max 120 130 140
VE/VO2 37.0 33.5 29.3
VE/VCO2 35.2 33.2 27.8
Hemodynamic and pulmonary parameters after inhibition of PDE5. BP = blood pressure, PAP = pulmonary arterial pressure, PVR = pulmonary 
vascular resistance, VO2peak = peak oxygen uptake, VE/VO2 ventilatory equivalent of oxygen; VE/VCO2 ventilatory equivalent of carbon dioxide. 
PAWP = pulmonary arterial wedged pressureJournal of Medical Case Reports 2007, 1:46 http://www.jmedicalcasereports.com/content/1/1/46
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Discussion and conclusion
Here we describe the reduction of both pulmonary arterial
and portal venous pressure in a patient with portopulmo-
nary hypertension by PDE5 inhibitors with a beneficial
effect on cardiac and pulmonary performance. Tadalafil –
a long acting PDE5 inhibitor – lowered PAPmean and pul-
monary arterial resistance within 60 minutes. There are
several reports on the effect of Sildenafil on PAPmean in
PPHTN [6]. However, the effect of a PDE5 inhibitor on
portal pressure in PPHTN has not yet been evaluated. The
data from the present patient confirms our previous
results [5]: In this study we had shown that in liver cirrho-
sis the PDE5 inhibitor Vardenafil induced a rapid increase
of portal venous blood flow by about 20–25% and a
decline of HVPG by about 20% in liver cirrhosis.
Wang et al. [7] reported on an increase of WHVP and
HVPG in a patient with PPHTN after Sildenafil accompa-
nied by an increase of arterial blood pressure and heart
rate. The latter effects are highly atypical for Sildenafil, so
one may speculate that other effects may have interfered
with the genuine effects of Sildenafil on portal pressure.
There are case reports about a correlation between Silde-
nafil intake and bleeding from esophageal varices. It was
speculated that Sildenafil may increase portal pressure.
However, these reports did not differentiate between
bleeding caused by sexual activity after Sildenafil intake
and a hypothetical deleterious effect of the drug on portal
pressure [8,9]. This case presentation and recent own
results [5] suggest that PDE5 inhibitors are no major risk
factor for bleeding from esophageal varices.
Data from animal experiments showed inconsistent
results for the effect of Sildenafil on portal flow and portal
pressure [10]. However, these data cannot be transferred
to the clinical setting, since Sildenafil was administered
intravenously or intraarterially as a bolus and at exces-
sively high doses resulting in drug levels several orders of
magnitude higher than after therapeutic oral application
in humans.
In our patient, 6 months treatment with Sildenafil
induced a marked improvement of exercise capacity. The
hemodynamic follow-up measurements after 6 months
therapy showed no additional effect of Sildenafil on PAP-
mean and pulmonary vascular resistance 8 hours after the
last dose. Probably even trough levels are sufficient to
exert the maximum dilating effect on the pulmonary ves-
sels. It may be speculated that PDE5 inhibition relieved
the vasoconstriction in the acute testing, but that a further
vasodilating effect could not be expected on the long
term. Unfortunately, the effect of Sildenafil in this situa-
tion could not be determined due to technical problems.
However, a deterioration of portal hemodynamics can be
excluded.
Beta-blockers for prevention of bleeding are contraindi-
cated in patients with PPHTN, since they worsen the pul-
monary hemodynamics by pulmonary vasoconstriction
and limitation of right ventricular function [3]. In analogy
to other forms of pulmonary arterial hypertension therapy
with PDE5 inhibitors is used in PPHTN. Our data add a
further rationale for application of these drugs since a
dual effect may be achieved, lowering of pulmonary and
portal pressure. The biochemical background for regula-
tion of sinusoidal tonus [1] suggests that PDE5 inhibitors
act by at least partially reversing the sinusoidal constric-
tion that is characteristic for liver cirrhosis. Our data sug-
gest that Sildenafil, Vardenafil, and Tadalafil, have
comparable effects on portal hemodynamics: oral admin-
istration of the drugs at doses, which are used for erectile
dysfunction, improves portal liver perfusion and induces
a drop of portal pressure or HVPG as is required for effec-
tive prevention of bleeding. Therefore, the potential ben-
eficial action of PDE5 inhibitors in liver cirrhosis should




cGMP cyclic guanosine monophosphate
CVP central venous pressure
eNOS endothelial NO-synthase
FHVP free hepatic venous pressure
HVPG hepato-venous pressure gradient
IPAH idiopathic pulmonary arterial hypertension
NO nitric oxide
WHVP wedged hepatic vein pressure
PAWP pulmonary arterial wedged pressure
PAP pulmonary arterial pressure
PAPmean mean pulmonary arterial pressure
PAPsystolic systolic pulmonary arterial pressure
PDE5 phosphodiesterase 5
PPHTN portopulmonary hypertension
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yGT gamma-glutamyltransferase
VE ventilatory equivalent
VO2peak peak oxygen uptake
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